论文部分内容阅读
目的:分析骨肉瘤预后的相关因素,评价骨肉瘤和多药耐药基因的关系。方法:检测骨肉瘤中MDR1/P-gp的表达,多因素统计生存分析。结果:84例骨肉瘤平均随访21.3个月,28.6%(24/84)1年内发生肺转移;3年生存率为42.9%;P-gp表达阳性率55.1%,等级相关分析显示P-gp表达与1年内肺转移率成等级正相关;COX模型分析显示:P-gp表达及扁骨部位骨肉瘤是无瘤生存期及生存时间的危险因素,年龄和病程是无瘤生存期及生存时间的保护因素。结论:骨肉瘤患者预后的高危因素是MDR1的表达及扁骨部位的骨肉瘤,保护因素是年龄和病程,大剂量新辅助化疗是改善骨肉瘤预后的关键。
Objective: To analyze the prognostic factors of osteosarcoma and to evaluate the relationship between osteosarcoma and multidrug resistance genes. Methods: The expression of MDR1 / P-gp in osteosarcoma was detected by multivariate statistical analysis. Results: 84 osteosarcoma patients were followed up for an average of 21.3 months. 28.2% (24 of 84) patients developed lung metastasis within one year. The 3-year survival rate was 42.9%. The positive rate of P-gp expression was 55.1%. The rank correlation analysis showed that P-gp expression COX model analysis showed that the expression of P-gp and osteosarcoma in oblate bone were risk factors for tumor-free survival and survival time. The age and course of disease were disease-free survival and survival time Protection factors. Conclusion: The risk factors for the prognosis of osteosarcoma are the expression of MDR1 and osteosarcoma in the oblate bone. The protective factors are age and course of disease. High dose neoadjuvant chemotherapy is the key to improve the prognosis of osteosarcoma.